Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 642
Filtrer
1.
JAMA ; 328(21): 2136-2146, 2022 12 06.
Article de Anglais | MEDLINE | ID: mdl-36472595

RÉSUMÉ

Importance: The Medicare Merit-based Incentive Payment System (MIPS) influences reimbursement for hundreds of thousands of US physicians, but little is known about whether program performance accurately captures the quality of care they provide. Objective: To examine whether primary care physicians' MIPS scores are associated with performance on process and outcome measures. Design, Setting, and Participants: Cross-sectional study of 80 246 US primary care physicians participating in the MIPS program in 2019. Exposures: MIPS score. Main Outcomes and Measures: The association between physician MIPS scores and performance on 5 unadjusted process measures, 6 adjusted outcome measures, and a composite outcome measure. Results: The study population included 3.4 million patients attributed to 80 246 primary care physicians, including 4773 physicians with low MIPS scores (≤30), 6151 physicians with medium MIPS scores (>30-75), and 69 322 physicians with high MIPS scores (>75). Compared with physicians with high MIPS scores, physicians with low MIPS scores had significantly worse mean performance on 3 of 5 process measures: diabetic eye examinations (56.1% vs 63.2%; difference, -7.1 percentage points [95% CI, -8.0 to -6.2]; P < .001), diabetic HbA1c screening (84.6% vs 89.4%; difference, -4.8 percentage points [95% CI, -5.4 to -4.2]; P < .001), and mammography screening (58.2% vs 70.4%; difference, -12.2 percentage points [95% CI, -13.1 to -11.4]; P < .001) but significantly better mean performance on rates of influenza vaccination (78.0% vs 76.8%; difference, 1.2 percentage points [95% CI, 0.0 to 2.5]; P = .045] and tobacco screening (95.0% vs 94.1%; difference, 0.9 percentage points [95% CI, 0.3 to 1.5]; P = .001). MIPS scores were inconsistently associated with risk-adjusted patient outcomes: compared with physicians with high MIPS scores, physicians with low MIPS scores had significantly better mean performance on 1 outcome (307.6 vs 316.4 emergency department visits per 1000 patients; difference, -8.9 [95% CI, -13.7 to -4.1]; P < .001), worse performance on 1 outcome (255.4 vs 225.2 all-cause hospitalizations per 1000 patients; difference, 30.2 [95% CI, 24.8 to 35.7]; P < .001), and did not have significantly different performance on 4 ambulatory care-sensitive admission outcomes. Nineteen percent of physicians with low MIPS scores had composite outcomes performance in the top quintile, while 21% of physicians with high MIPS scores had outcomes in the bottom quintile. Physicians with low MIPS scores but superior outcomes cared for more medically complex and socially vulnerable patients, compared with physicians with low MIPS scores and poor outcomes. Conclusions and Relevance: Among US primary care physicians in 2019, MIPS scores were inconsistently associated with performance on process and outcome measures. These findings suggest that the MIPS program may be ineffective at measuring and incentivizing quality improvement among US physicians.


Sujet(s)
Medicare (USA) , Évaluation des résultats et des processus en soins de santé , Soins de santé primaires , Qualité des soins de santé , Remboursement incitatif , Sujet âgé , Humains , Études transversales , Medicare (USA)/économie , Medicare (USA)/normes , Évaluation des résultats et des processus en soins de santé/économie , Évaluation des résultats et des processus en soins de santé/normes , Médecins de premier recours/économie , Soins de santé primaires/économie , Soins de santé primaires/normes , Qualité des soins de santé/économie , Qualité des soins de santé/normes , Remboursement incitatif/économie , États-Unis
2.
BMC Cardiovasc Disord ; 22(1): 64, 2022 02 22.
Article de Anglais | MEDLINE | ID: mdl-35193503

RÉSUMÉ

BACKGROUND: Globally the burden of heart failure is rising. Hospitalisation is one of the main contributors to the burden of heart failure and unfortunately, the majority of heart failure patients will experience multiple hospitalisations over their lifetime. Considering the high health care cost associated with heart failure, a review of economic evaluations of post-discharge heart failure services is warranted. AIM: An integrated review of the economic evaluations of post-discharge nurse-led heart failure services for patients hospitalised with acute heart failure. METHODS: Electronic databases were searched using EBSCOHost: CINAHL complete, Medline complete, Embase, Scopus, EconLit, Global Health, and Health source (Consumer and Nursing/Academic) for published articles until 22nd June 2021. The searches focussed on papers that examined the cost-effectiveness of nurse-led clinics or telemonitoring involving nurses to follow-up patients after hospitalisation for acute heart failure. GRADE criteria and CHEERS checklist were used to determine the quality of the evidence and the quality of reporting of the economic evaluation. RESULTS: Out of 453 studies identified, eight studies were included: four in heart failure clinics and four in telemonitoring programs. Five of the articles were cost-effectiveness analyses, one a cost comparison and two studies involved economic modelling The GRADE criteria were rated as high in five studies. In which, four studies examined the cost-effectiveness of telemonitoring programs. Based on the CHEERS checklist for reporting quality of economic evaluations, the majority of economic evaluations were rated between 86 and 96%. All the studies found the intervention to be cost-effective compared to usual care with Incremental Cost Effectiveness Ratios ranging from $18 259 (Canadian dollars)/life year gained to €40,321 per Quality Adjusted Life Years gained. CONCLUSION: Nurse-led heart failure clinics and telemonitoring programs were found to be cost-effective. Certainly, this review has shown that heart failure clinics and telemonitoring programs do represent value for money with their greatest impact and cost savings through reducing rehospitalisations.


Sujet(s)
Soins ambulatoires , Service hospitalier de cardiologie , Défaillance cardiaque/soins infirmiers , Rôle de l'infirmier , Personnel infirmier hospitalier , Évaluation des résultats et des processus en soins de santé , Soins ambulatoires/économie , Service hospitalier de cardiologie/économie , Économies , Analyse coût-bénéfice , Défaillance cardiaque/diagnostic , Défaillance cardiaque/mortalité , Défaillance cardiaque/physiopathologie , Coûts hospitaliers , Humains , Leadership , Personnel infirmier hospitalier/économie , Évaluation des résultats et des processus en soins de santé/économie , Résultat thérapeutique
3.
Clin J Am Soc Nephrol ; 16(10): 1522-1530, 2021 10.
Article de Anglais | MEDLINE | ID: mdl-34620648

RÉSUMÉ

BACKGROUND AND OBJECTIVES: Medicare plans to extend financial structures tested through the Comprehensive End-Stage Renal Disease Care (CEC) Initiative-an alternative payment model for maintenance dialysis providers-to promote high-value care for beneficiaries with kidney failure. The End-Stage Renal Disease Seamless Care Organizations (ESCOs) that formed under the CEC Initiative varied greatly in their ability to generate cost savings and improve patient health outcomes. This study examined whether organizational or community characteristics were associated with ESCOs' performance. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used a retrospective pooled cross-sectional analysis of all 37 ESCOs participating in the CEC Initiative during 2015-2018 (n=87 ESCO-years). Key exposures included ESCO characteristics: number of dialysis facilities, number and types of physicians, and years of CEC Initiative experience. Outcomes of interest included were above versus below median gross financial savings (2.4%) and standardized mortality ratio (0.93). We analyzed unadjusted differences between high- and low-performing ESCOs and then used multivariable logistic regression to construct average marginal effect estimates for parameters of interest. RESULTS: Above-median gross savings were obtained by 23 (52%) ESCOs with no program experience, 14 (32%) organizations with 1 year of experience, and seven (16%) organizations with 2 years of experience. The adjusted likelihoods of achieving above-median gross savings were 23 (95% confidence interval, 8 to 37) and 48 (95% confidence interval, 24 to 68) percentage points higher for ESCOs with 1 or 2 years of program experience, respectively (versus none). The adjusted likelihood of achieving above-median gross savings was 1.7 (95% confidence interval, -3 to -1) percentage points lower with each additional affiliated dialysis facility. Adjusted mortality rates were lower for ESCOs located in areas with higher socioeconomic status. CONCLUSIONS: Smaller ESCOs, organizations with more experience in the CEC Initiative, and those located in more affluent areas performed better under the CEC Initiative.


Sujet(s)
Accountable care organizations (USA)/organisation et administration , Prestation intégrée de soins de santé/organisation et administration , Défaillance rénale chronique/thérapie , Medicare (USA)/organisation et administration , Évaluation des résultats et des processus en soins de santé/organisation et administration , Dialyse rénale , Accountable care organizations (USA)/économie , Économies , Analyse coût-bénéfice , Études transversales , Prestation intégrée de soins de santé/économie , Coûts des soins de santé , Humains , Défaillance rénale chronique/diagnostic , Défaillance rénale chronique/économie , Défaillance rénale chronique/mortalité , Medicare (USA)/économie , Caractéristiques du voisinage , Évaluation des résultats et des processus en soins de santé/économie , Assurance de la qualité des soins de santé/organisation et administration , Indicateurs qualité santé/organisation et administration , Dialyse rénale/effets indésirables , Dialyse rénale/économie , Dialyse rénale/mortalité , Études rétrospectives , Classe sociale , Facteurs temps , Résultat thérapeutique , États-Unis
4.
J Am Heart Assoc ; 10(16): e020528, 2021 08 17.
Article de Anglais | MEDLINE | ID: mdl-34387132

RÉSUMÉ

Background Evidence suggests intracerebral hemorrhage survivors have earlier recovery compared with ischemic stroke survivors. The Centers for Medicare and Medicaid Services prospective payment system instituted documentation rules for inpatient rehabilitation facilities (IRFs) in 2010, with the goal of optimizing patient selection. We investigated whether these requirements limited IRF and increased skilled nursing facility (SNF) use compared with home discharge. Methods and Results Intracerebral hemorrhage discharges to IRF, SNF, or home were estimated using GWTG (Get With The Guidelines) Stroke registry data between January 1, 2008, and December 31, 2015 (n=265 444). Binary hierarchical models determined associations between the 2010 Rule and discharge setting; subgroup analyses evaluated age, geographic region, and hospital type. From January 1, 2008, to December 31, 2009, 45.5% of patients with intracerebral hemorrhage had home discharge, 22.2% went to SNF, and 32.3% went to IRF. After January 1, 2010, there was a 1.06% absolute increase in home discharge, a 0.46% increase in SNF, and a 1.52% decline in IRF. The adjusted odds of IRF versus home discharge decreased 3% after 2010 (adjusted odds ratio [aOR], 0.97; 95% CI, 0.95-1.00). Lower odds of IRF versus home discharge were observed in people aged <65 years (aOR, 0.92; 95% CI, 0.89-0.96), Western states (aOR, 0.89; 95% CI, 0.84-0.95), and nonteaching hospitals (aOR, 0.90; 95% CI, 0.86-0.95). Adjusted odds of SNF versus home discharge increased 14% after 2010 (aOR, 1.14; 95% CI, 1.11-1.18); there were significant associations in all age groups, the Northeast, the South, the Midwest, and teaching hospitals. Conclusions The Centers for Medicare and Medicaid Services 2010 IRF prospective payment system Rule resulted in fewer discharges to IRF and more discharges to SNF in patients with intracerebral hemorrhage. Health policy changes potentially affect access to intensive postacute rehabilitation.


Sujet(s)
Hémorragie cérébrale/rééducation et réadaptation , Réforme des soins de santé , Medicare (USA) , Évaluation des résultats et des processus en soins de santé/tendances , Sortie du patient/tendances , Système de paiements préétablis , Centres de rééducation et de réadaptation/tendances , Établissements de soins qualifiés/tendances , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Réforme des soins de santé/économie , Réforme des soins de santé/législation et jurisprudence , Accessibilité des services de santé/tendances , Humains , Patients hospitalisés , Mâle , Medicare (USA)/économie , Medicare (USA)/législation et jurisprudence , Adulte d'âge moyen , Évaluation des résultats et des processus en soins de santé/économie , Évaluation des résultats et des processus en soins de santé/législation et jurisprudence , Sortie du patient/économie , Sortie du patient/législation et jurisprudence , Processus politique , Système de paiements préétablis/économie , Système de paiements préétablis/législation et jurisprudence , Enregistrements , Centres de rééducation et de réadaptation/économie , Centres de rééducation et de réadaptation/législation et jurisprudence , Établissements de soins qualifiés/économie , Établissements de soins qualifiés/législation et jurisprudence , Facteurs temps , Résultat thérapeutique , États-Unis
5.
J Stroke Cerebrovasc Dis ; 30(10): 106016, 2021 Oct.
Article de Anglais | MEDLINE | ID: mdl-34325273

RÉSUMÉ

OBJECTIVES: Transient ischemic attack (TIA) can be a warning sign of an impending stroke. The objective of our study is to assess the feasibility, safety, and cost savings of a comprehensive TIA protocol in the emergency room for low-risk TIA patients. MATERIALS AND METHODS: This is a retrospective, single-center cohort study performed at an academic comprehensive stroke center. We implemented an emergency department-based TIA protocol pathway for low-risk TIA patients (defined as ABCD2 score < 4 and without significant vessel stenosis) who were able to undergo vascular imaging and a brain MRI in the emergency room. Patients were set up with rapid outpatient follow-up in our stroke clinic and scheduled for an outpatient echocardiogram, if indicated. We compared this cohort to TIA patients admitted prior to the implementation of the TIA protocol who would have qualified. Outcomes of interest included length of stay, hospital cost, radiographic and echocardiogram findings, recurrent neurovascular events within 30 days, and final diagnosis. RESULTS: A total of 138 patients were assessed (65 patients in the pre-pathway cohort, 73 in the expedited, post-TIA pathway implementation cohort). Average time from MRI order to MRI end was 6.4 h compared to 2.3 h in the pre- and post-pathway cohorts, respectively (p < 0.0001). The average length of stay for the pre-pathway group was 28.8 h in the pre-pathway cohort compared to 7.7 h in the post-pathway cohort (p < 0.0001). There were no differences in neuroimaging or echocardiographic findings. There were no differences in the 30 days re-presentation for stroke or TIA or mortality between the two groups. The direct cost per TIA admission was $2,944.50 compared to $1,610.50 for TIA patients triaged through the pathway at our institution. CONCLUSIONS: This study demonstrates the feasibility, safety, and cost-savings of a comprehensive, emergency department-based TIA protocol. Further study is needed to confirm overall benefit of an expedited approach to TIA patient management and guide clinical practice recommendations.


Sujet(s)
Prestation intégrée de soins de santé/économie , Service hospitalier d'urgences/économie , Coûts hospitaliers , Accident ischémique transitoire/économie , Accident ischémique transitoire/thérapie , Évaluation des résultats et des processus en soins de santé/économie , Sujet âgé , Sujet âgé de 80 ans ou plus , Protocoles cliniques , Économies , Analyse coût-bénéfice , Techniques d'aide à la décision , Études de faisabilité , Femelle , Humains , Accident ischémique transitoire/imagerie diagnostique , Accident ischémique transitoire/mortalité , Durée du séjour/économie , Mâle , Adulte d'âge moyen , Valeur prédictive des tests , Études rétrospectives , Appréciation des risques , Facteurs de risque , Facteurs temps , Résultat thérapeutique , Triage/économie
6.
J Stroke Cerebrovasc Dis ; 30(8): 105931, 2021 Aug.
Article de Anglais | MEDLINE | ID: mdl-34157669

RÉSUMÉ

OBJECTIVES: The Quality in Acute Stroke Care (QASC) protocol is a multidisciplinary approach to implement evidence-based treatment after acute stroke that reduces death and disability. This study sought to evaluate the cost-effectiveness of implementing the QASC protocol across Australia, from a healthcare and a societal perspective. MATERIALS AND METHODS: A decision-analytic model was constructed to reflect one-year outcomes post-stroke, aligned with the stroke severity categories of the modified Rankin scale (mRS). Decision analysis compared outcomes following implementation of the QASC protocol versus no implementation. Population data were extracted from Australian databases and data inputs regarding stroke incidence, costs, and utilities were drawn from published sources. The analysis assumed a progressive uptake and efficacy of the QASC protocol over five years. Health benefits and costs were discounted by 5% annually. The cost of each year lived by an Australian, from a societal perspective, was based on the Australian Government's 'value of statistical life year' (AUD 213,000). RESULTS: Over five years, the model predicted 263,722 strokes among the Australian population. The implementation of the QASC protocol was predicted to prevent 1,154 deaths and yield a gain of 876 years of life (0.003 per stroke), and 3,180 quality-adjusted life years (QALYs) (0.012 per stroke). There was an estimated net saving of AUD 65.2 million in healthcare costs (AUD 247 per stroke) and AUD 251.7 million in societal costs (AUD 955 per stroke). CONCLUSIONS: Implementation of the QASC protocol in Australia represents both a dominant (cost-saving) strategy, from a healthcare and a societal perspective.


Sujet(s)
Protocoles cliniques , Coûts des soins de santé , Évaluation des résultats et des processus en soins de santé/économie , Amélioration de la qualité/économie , Indicateurs qualité santé/économie , Accident vasculaire cérébral/thérapie , Australie/épidémiologie , Économies , Analyse coût-bénéfice , Techniques d'aide à la décision , Évaluation de l'invalidité , État fonctionnel , Humains , Incidence , Évaluation de programme , Qualité de vie , Années de vie ajustées sur la qualité , Accident vasculaire cérébral/diagnostic , Accident vasculaire cérébral/épidémiologie , Facteurs temps , Résultat thérapeutique
7.
Ann Vasc Surg ; 76: 142-151, 2021 Oct.
Article de Anglais | MEDLINE | ID: mdl-34153489

RÉSUMÉ

OBJECTIVES: The creation and maintenance of durable hemodialysis access is critically important for reducing patient morbidity and controlling overall costs within health systems. Our objective was to quantify the costs associated with hemodialysis access creation and its maintenance over time within a rate-controlled health system where charges equate to payments. METHODS: The Maryland Health Services Cost Review Commission administrative claims database was used to identify patients who underwent first-time access creation from 2012-2020. Patients were identified using CPT codes for access creation, and costs were accrued for the initial encounter and all subsequent outpatient access-related encounters. T-tests and Wilcoxon tests were used to compare reinterventions and access-related costs ($USD) between arteriovenous fistulae (AVF) and arteriovenous grafts (AVG). Multivariable modeling was used to quantify the association of access type with charge variation. RESULTS: Overall, 12,716 patients underwent first-time access creation (69.3% AVF vs. 30.7% AVG). There was no difference in freedom from reintervention between the two access types at any point following creation (HR: 1.03, 95%CI: 0.97-1.10); however, AVF were associated with a lower number of cumulative reinterventions (1.50 vs. 2.24) compared to AVG (P<0.0001). AVF was associated with lower overall costs in the year of creation ($9,388 vs. $13,539, P<0.0001), a difference that remained significant over the subsequent 3 years. The lower costs associated with AVF were present both in the costs associated with creation and subsequent maintenance. On multivariable analysis, AVF was associated with a $3,557 reduction in total access-related costs versus AVG (95%CI -$3828, -3287). CONCLUSION: AVF require fewer interventions and are associated with lower costs at placement and over the first three years of maintenance compared to AVG. The use of AVF for first-time hemodialysis access represents an opportunity for healthcare savings in appropriately selected patients with a high preoperative likelihood of AVF maturation.


Sujet(s)
Anastomose chirurgicale artérioveineuse/économie , Implantation de prothèses vasculaires/économie , Coûts des soins de santé , Plans de systèmes de santé/économie , Défaillance rénale chronique/économie , Défaillance rénale chronique/thérapie , Évaluation des résultats et des processus en soins de santé/économie , Dialyse rénale/économie , Données administratives des demandes de remboursement des soins de santé , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Économies , Analyse coût-bénéfice , Femelle , Humains , Défaillance rénale chronique/diagnostic , Mâle , Maryland , Adulte d'âge moyen , Réintervention/économie , Études rétrospectives , Facteurs temps , Résultat thérapeutique
8.
Ann Vasc Surg ; 76: 179-184, 2021 Oct.
Article de Anglais | MEDLINE | ID: mdl-34153493

RÉSUMÉ

OBJECTIVE: The use of radiographic evaluation of carotid disease may vary, and current guidelines do not strongly recommend the use of cross-sectional imaging (CSI) prior to surgical intervention. We sought to describe the trends in preoperative carotid imaging and evaluate the associated clinical outcomes and Medicare payments for patients undergoing carotid endarterectomy (CEA) for asymptomatic carotid disease. METHODS: We used a 20% Medicare sample from 2006 to 2014 identifying patients undergoing CEA for asymptomatic disease. We evaluated preoperative carotid ultrasound and CSI use: CT or MRI of the neck prior to CEA. We calculated average payments of each study from the carrier file and revenue center file. Imaging payments included both the professional component (PC) and the technical component (TC). Claims with a reimbursement of $0 and studies where payment for both the TC and PC could not be identified were excluded from the overall calculation to determine average payment per study. Inpatient reimbursements according to DRG 37-39 were calculated. We compared hospital length of stay (LOS), in hospital stroke, carotid re-exploration, and mortality according to CSI use. RESULTS: A total of 58,993 CEAs were identified with pre-operative carotid imaging. The average age was 74.8 ± 7.5 years, and 56.0% were men. A total of 19,678 (33%) patients had ultrasound alone with an average of (2.4 ± 1.9) exams prior to CEA. A total of 39,315 patients underwent CSI prior to CEA with 2.5 ± 2.1 ultrasounds, 0.95 ± 0.86 neck CTs and 0.47 ± 0.7 MRIs per patient. The average payment for ultrasound was $140 ± 40, $282 ± 94 for CT and $410 ± 146 for MRI. The average inpatient reimbursements were $7,413 ± 4,215 for patients without CSI compared with $7,792 ± 3,921 for patients with CSI, P < 0.001. The average LOS during CEA admission was 2.5 ± 3.7days. Patients with CSI had a slightly lower percentage of patients being discharged by postoperative day 2 compared with ultrasound alone (88.9% vs. 91.5%, respectively, P < 0.001). The overall in-hospital stroke rate was 0.38% and carotid re-exploration rate was 1.0% and there was no statistical significant difference between groups. Median follow-up was 3.9 years, and mortality at 8 years was 50% and did not statistically differ between groups. CONCLUSIONS: Our analysis found preoperative imaging to include CSI in nearly two-thirds of patients prior to CEA for asymptomatic disease. As imaging and inpatient payments were higher with patients with CSI further work is needed to understand when CSI is appropriate prior to surgical intervention to appropriately allocate healthcare resources.


Sujet(s)
Artériopathies carotidiennes/économie , Endartériectomie carotidienne/économie , Coûts hospitaliers , Remboursement par l'assurance maladie/économie , Imagerie par résonance magnétique/économie , Medicare (USA)/économie , Évaluation des résultats et des processus en soins de santé/économie , Tomodensitométrie/économie , Échographie/économie , Sujet âgé , Sujet âgé de 80 ans ou plus , Maladies asymptomatiques , Artériopathies carotidiennes/imagerie diagnostique , Artériopathies carotidiennes/mortalité , Artériopathies carotidiennes/chirurgie , Prise de décision clinique , Analyse coût-bénéfice , Endartériectomie carotidienne/effets indésirables , Endartériectomie carotidienne/mortalité , Femelle , Humains , Durée du séjour/économie , Mâle , Valeur prédictive des tests , Réintervention/économie , Études rétrospectives , Facteurs temps , Résultat thérapeutique , États-Unis
9.
Methodist Debakey Cardiovasc J ; 17(1): e1-e9, 2021 Apr 05.
Article de Anglais | MEDLINE | ID: mdl-34104328

RÉSUMÉ

Patient-reported outcomes (PROs) are elicited directly from patients so they can describe their overall health status, including their symptoms, function, and quality of life. While commonly used as end points in clinical trials, PROs can play an important role in routine clinical care, population health management, and as a means for quantifying the quality of patient care. In this review, we propose that PROs be used to improve patient-centered care in the treatment of cardiovascular diseases given their importance to patients and society and their ability to improve doctor- provider communication. Furthermore, given the current variability in patients' health status across different clinics and the fact that PROs can be improved by titrating therapy, we contend that PROs have a key opportunity to serve as measures of healthcare quality.


Sujet(s)
Maladies cardiovasculaires/thérapie , Évaluation des résultats et des processus en soins de santé/normes , Mesures des résultats rapportés par les patients , Soins centrés sur le patient/normes , Amélioration de la qualité/normes , Indicateurs qualité santé/normes , Maladies cardiovasculaires/diagnostic , Maladies cardiovasculaires/économie , Analyse coût-bénéfice , État fonctionnel , Coûts des soins de santé , Humains , Évaluation des résultats et des processus en soins de santé/économie , Soins centrés sur le patient/économie , Psychométrie , Amélioration de la qualité/économie , Indicateurs qualité santé/économie , Qualité de vie , Résultat thérapeutique
10.
Eur J Cancer ; 151: 126-135, 2021 07.
Article de Anglais | MEDLINE | ID: mdl-33979728

RÉSUMÉ

BACKGROUND: Although different treatment protocols for childhood acute lymphoblastic leukaemia (ALL) all achieve high cure rates, their health care utilisation and costs have not been rigorously compared. METHODS: Disease, treatment, and outcome data were chart abstracted for all children with ALL in Ontario, Canada, diagnosed 2002-2012. Linkage to population-based databases identified health care utilisation. Utilisation-associated costs were determined through validated algorithms. Chemotherapy-associated costs were calculated separately. Health care utilisation and costs were compared between patients receiving Children's Oncology Group (COG) versus Dana-Farber Cancer Institute (DFCI)-based treatment. FINDINGS: Of 802 patients, 146 (18.2%) were treated on DFCI-based protocols. COG patients experienced significantly higher rates of emergency department (ED) visits (adjusted rate ratio [aRR]: 1.3, 95% confidence interval [CI]: 1.1-1.5; p = 0·01), whereas outpatient visit rates were 60% higher among DFCI patients (aRR: 1.6, 95% CI: 1.5-1.7, p < 0.0001). In adjusted analyses, DFCI-associated cost intensity was 70% higher (aRR: 1.7, 95% CI: 1.5-1.9; p < 0.0001), mainly attributable to outpatient visit costs. Total chemotherapy costs were higher among COG-treated patients ($39,400 ± $1100 versus $33,400 ± $2800; p = 0.02). Among PEG-ASNase-treated patients, total chemotherapy costs were highest among DFCI patients (median $54,200 ± $7400; p = 0.003 versus COG patients). INTERPRETATION: COG and DFCI treatments were associated with higher ED visit rates and higher outpatient visit rates, respectively. Overall utilisation-associated costs were increased in DFCI-treated patients. Administration of some intravenous chemotherapy at home and decreases in PEG-ASNase cost would decrease health care utilisation and costs for all patients and mitigate differences between COG and DFCI protocols. FUNDING: C17 Research Network.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/économie , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Coûts des médicaments , Coûts hospitaliers , Évaluation des résultats et des processus en soins de santé/économie , Leucémie-lymphome lymphoblastique à précurseurs B et T/traitement médicamenteux , Leucémie-lymphome lymphoblastique à précurseurs B et T/économie , Adolescent , Soins ambulatoires/économie , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Enfant , Enfant d'âge préscolaire , Protocoles cliniques , Analyse coût-bénéfice , Service hospitalier d'urgences/économie , Femelle , Dépenses de santé , Recherche sur les services de santé , Humains , Nourrisson , Mâle , Ontario , Leucémie-lymphome lymphoblastique à précurseurs B et T/diagnostic , Facteurs temps , Résultat thérapeutique
11.
J Stroke Cerebrovasc Dis ; 30(7): 105802, 2021 Jul.
Article de Anglais | MEDLINE | ID: mdl-33866272

RÉSUMÉ

While use of telemedicine to guide emergent treatment of ischemic stroke is well established, the COVID-19 pandemic motivated the rapid expansion of care via telemedicine to provide consistent care while reducing patient and provider exposure and preserving personal protective equipment. Temporary changes in re-imbursement, inclusion of home office and patient home environments, and increased access to telehealth technologies by patients, health care staff and health care facilities were key to provide an environment for creative and consistent high-quality stroke care. The continuum of care via telestroke has broadened to include prehospital, inter-facility and intra-facility hospital-based services, stroke telerehabilitation, and ambulatory telestroke. However, disparities in technology access remain a challenge. Preservation of reimbursement and the reduction of regulatory burden that was initiated during the public health emergency will be necessary to maintain expanded patient access to the full complement of telestroke services. Here we outline many of these initiatives and discuss potential opportunities for optimal use of technology in stroke care through and beyond the pandemic.


Sujet(s)
COVID-19 , Continuité des soins , Prestation intégrée de soins de santé , Accident vasculaire cérébral ischémique/thérapie , Évaluation des résultats et des processus en soins de santé , Télémédecine , Continuité des soins/économie , Prestation intégrée de soins de santé/économie , Régimes de rémunération à l'acte , Coûts des soins de santé , Disparités d'accès aux soins , Humains , Remboursement par l'assurance maladie , Accident vasculaire cérébral ischémique/diagnostic , Accident vasculaire cérébral ischémique/économie , Santé au travail , Évaluation des résultats et des processus en soins de santé/économie , Sécurité des patients , Télémédecine/économie
12.
BMC Pregnancy Childbirth ; 21(1): 333, 2021 Apr 26.
Article de Anglais | MEDLINE | ID: mdl-33902486

RÉSUMÉ

BACKGROUND: Healthcare costs have substantially increased in recent years, threatening the population health. Obstetric care is a significant contributor to this scenario since it represents 20% of healthcare. The rate of cesarean sections (C-sections) has escalated worldwide. Evidence shows that cesarean delivery is not only more expensive, but it is also linked to poorer maternal and neonatal outcomes. This study assesses which type of delivery is associated with a higher healthcare value in low-risk pregnancies. RESULTS: A total of 9345 deliveries were analyzed. The C-section group had significantly worse rates of breastfeeding in the first hour after delivery (92.57% vs 88.43%, p < 0.001), a higher rate of intensive unit care (ICU) admission both for the mother and the newborn (0.8% vs 0.3%, p = 0.001; 6.7% vs 4.5%, p = 0.0078 respectively), and a higher average cost of hospitalization (BRL14,342.04 vs BRL12,230.03 considering mothers and babies). CONCLUSION: Cesarean deliveries in low-risk pregnancies were associated with a lower value delivery because in addition to being more expensive, they had worse perinatal outcomes.


Sujet(s)
Césarienne , Accouchement (procédure) , Coûts des soins de santé , Coûts hospitaliers/statistiques et données numériques , Obstétrique/économie , Adulte , Brésil/épidémiologie , Allaitement naturel/statistiques et données numériques , Césarienne/économie , Césarienne/méthodes , Césarienne/statistiques et données numériques , Prestations des soins de santé/organisation et administration , Prestations des soins de santé/tendances , Accouchement (procédure)/économie , Accouchement (procédure)/méthodes , Accouchement (procédure)/statistiques et données numériques , Femelle , Coûts des soins de santé/statistiques et données numériques , Coûts des soins de santé/tendances , Humains , Nouveau-né , Unités de soins intensifs/statistiques et données numériques , Évaluation des résultats et des processus en soins de santé/économie , Évaluation des résultats et des processus en soins de santé/statistiques et données numériques , Grossesse , Appréciation des risques
13.
BMC Cardiovasc Disord ; 21(1): 155, 2021 03 26.
Article de Anglais | MEDLINE | ID: mdl-33771104

RÉSUMÉ

BACKGROUND: The study evaluated the cost of baroreflex activation therapy plus guideline directed therapy (BAT + GDT) compared to GDT alone for HF patients with reduced ejection fraction and New York Heart Association Class III or II (with a recent history of III). Baroreflex activation therapy (BAT) is delivered by an implantable device that stimulates the baroreceptors through an electrode attached to the outside of the carotid artery, which rebalances the autonomic nervous system to regain cardiovascular (CV) homeostasis. The BeAT-HF trial evaluated the safety and effectiveness of BAT. METHODS: A cost impact model was developed from a U.S. health care payer or integrated delivery network perspective over a 3-year period for BAT + GDT versus GDT alone. Expected costs were calculated by utilizing 6-month data from the BeAT-HF trial and existing literature. HF hospitalization rates were extrapolated based on improvement in NT-proBNP. RESULTS: At baseline the expected cost of BAT + GDT were $29,526 per patient more than GDT alone due to BAT device and implantation costs. After 3 years, the predicted cost per patient was $9521 less expensive for BAT + GDT versus GDT alone due to lower rates of significant HF hospitalizations, CV non-HF hospitalizations, and resource intensive late-stage procedures (LVADs and heart transplants) among the BAT + GDT group. CONCLUSIONS: BAT + GDT treatment becomes less costly than GDT alone beginning between years 1 and 2 and becomes less costly cumulatively between years 2 and 3, potentially providing significant savings over time. As additional BeAT-HF trial data become available, the model can be updated to show longer term effects.


Sujet(s)
Baroréflexe , Électrothérapie/économie , Coûts des soins de santé , Défaillance cardiaque/économie , Défaillance cardiaque/thérapie , Évaluation des résultats et des processus en soins de santé/économie , Barorécepteurs/physiopathologie , Maladie chronique , Économies , Analyse coût-bénéfice , Électrothérapie/effets indésirables , Défaillance cardiaque/diagnostic , Défaillance cardiaque/physiopathologie , Humains , Modèles économiques , Facteurs temps , Résultat thérapeutique , États-Unis
14.
J Stroke Cerebrovasc Dis ; 30(5): 105705, 2021 May.
Article de Anglais | MEDLINE | ID: mdl-33711759

RÉSUMÉ

OBJECTIVES: To investigate the effects of hydration with or without Hydroxyethyl Starch (HES) 130/0.4 on neurological outcomes and medical costs during hospitalisation in patients with a single infarction (SI) in the posterior lenticulostriate artery (LSA) territory. MATERIALS AND METHODS: In this retrospective, single-centre, non-blinded cohort study, SI in the posterior LSA was defined as an ischaemic lesion with a high-signal intensity area ≥20 mm. All patients received basic stroke care within 48 h of symptom onset between April 2015 and January 2019. Patients were divided into the following two groups by clinician's preference: 1) those administered HES 130/0.4 and 2) those receiving other infusion fluid. The relationships between hospital costs and hydration therapy type were examined. RESULTS: Eighteen (31%) of 58 patients received HES 130/0.4. The HES group had a significantly lower total cost than the control group (3.6 vs. 6.4 million yen, p=0.006). Moreover, the HES group had a significantly shorter hospital stay duration (79.5 vs. 141.0 days) and lower National Institutes of Health Stroke Scale score on day 7. Multivariate analysis found that HES 130/0.4 administration was an independent factor associated with high costs. CONCLUSIONS: Hydration therapy with HES 130/0.4 significantly decreased the total costs and hospitalisation duration of patients with SI in the posterior LSA territory.


Sujet(s)
Infarctus encéphalique/économie , Infarctus encéphalique/thérapie , Traitement par apport liquidien/économie , Coûts hospitaliers , Hydroxyéthylamidons/économie , Hydroxyéthylamidons/usage thérapeutique , Évaluation des résultats et des processus en soins de santé/économie , Substituts du plasma/économie , Substituts du plasma/usage thérapeutique , Sujet âgé , Infarctus encéphalique/diagnostic , Économies , Analyse coût-bénéfice , Femelle , Traitement par apport liquidien/effets indésirables , Humains , Hydroxyéthylamidons/effets indésirables , Durée du séjour/économie , Mâle , Adulte d'âge moyen , Substituts du plasma/effets indésirables , Études rétrospectives , Facteurs temps , Résultat thérapeutique
15.
J Vasc Surg ; 73(2): 494-501, 2021 02.
Article de Anglais | MEDLINE | ID: mdl-32473346

RÉSUMÉ

BACKGROUND: In the current era of cost containment, the financial impact of high-cost procedures such as endovascular aneurysm repair (EVAR) remains an area of intensive interest. Previous reports suggested slim to negative operating margins with EVAR, prompting widespread initiatives to reduce cost and to improve reimbursement. In 2015, the Centers for Medicare and Medicaid Services (CMS) announced the reclassification of EVAR to more specific diagnosis-related group (DRG) coding and predicted an overall increase in hospital reimbursement. The potential impact of this change has not been described. METHODS: Patients undergoing elective EVAR at a single institution between January 2014 and December 2018 were identified retrospectively, then stratified by date. Group 1 patients underwent EVAR before DRG change in 2015 and were classified with DRG 237/238, major cardiovascular procedure. Group 2 patients underwent EVAR after the change and were classified as DRG 268/269, aortic/heart assist procedures. The total direct cost included implant cost, operating room (OR) labor, room and board, and other supply costs. Net revenue reflected real payer mix values without extrapolation based on standard Medicare rates. Hospital profit was defined as the contribution to indirect (CTI), subtracting total direct cost from net revenue. RESULTS: A total of 188 encounters were included, 67 (36%) in group 1 and 121 (64%) in group 2. Medicare patients composed 84% of group 1 and 81% of group 2. CTI (profit) increased by $4447 (+123%) from $3615 in group 1 to $8062 in group 2. Net revenue per encounter increased by $2054 (+7.1%). In group 1, the higher reimbursement DRG code 237 was applied in 5 of 67 (7.5%) patients, whereas DRG code 268 was assigned in 19 of 121 (15.1%) patients in group 2. Total direct cost per encounter decreased by $2012 (-7.9%). This decrease in cost was driven by a reduction in implant cost, from a mean $16,914 per encounter in group 1 to a mean $15,655 in group 2 (-$1259 or -7.4% per encounter) and by a decrease in OR labor cost, $2838 in group 1 to $2361 in group 2 (-$477 or -17.0% per encounter). CONCLUSIONS: A significant improvement in hospital CTI was observed for elective EVAR during the course of the study. The increased DRG reimbursement after the Centers for Medicare and Medicaid Services coding changes in 2015 was a major driver of this salutary change. Notably, efforts to reduce implant and OR cost as well as to improve coding and documentation accuracy over time had an equally important impact on financial return.


Sujet(s)
Anévrysme/économie , Anévrysme/chirurgie , Implantation de prothèses vasculaires/économie , Procédures endovasculaires/économie , Régimes de rémunération à l'acte , Coûts hospitaliers , Remboursement par l'assurance maladie , Évaluation des résultats et des processus en soins de santé/économie , Prothèse vasculaire/économie , Implantation de prothèses vasculaires/instrumentation , /économie , Analyse coût-bénéfice , Groupes homogènes de malades/économie , Procédures endovasculaires/instrumentation , Humains , Études rétrospectives , Facteurs temps , Résultat thérapeutique , États-Unis
16.
Transplantation ; 105(2): 404-412, 2021 02 01.
Article de Anglais | MEDLINE | ID: mdl-32265414

RÉSUMÉ

BACKGROUND: Nationwide studies on the effects of wealth inequality on kidney transplantation are rare, particularly in a country with an expanded National Health Insurance Service and in Asian countries. METHODS: In this nationwide, population-based cohort study, we reviewed the national claims database of Korea in which details of nationwide health insurance are provided. From 2007 to 2015, 9 annual cohorts of end-stage renal disease patients were included. The annual financial statuses were collected and stratified into 5 subgroups in each year: the aided group in which insurance fee was waived and the 4 other groups divided by quartiles of their medical insurance fee. Time trends of incidence proportion of kidney transplantation among end-stage renal disease patients in each year were initially assessed. The risk of graft failure, both including death-censored graft failure and death with a functioning graft, was analyzed as a prognostic outcome within the transplant recipients. RESULTS: Significant disparity in the accessibility of kidney transplantation was present, and it was further widening, particularly from 2009 in which the National Health Insurance Service started to cover desensitized kidney transplantation. Desensitized or preemptive transplantation was less common in the poorest group who were more frequently receiving transplantation after 5 years of dialysis in the latter years. The prognosis of kidney transplantation was significantly worse in the poorer people, and this disparity also worsened during the study period. CONCLUSIONS: Prominent disparity regarding accessibility to and prognosis of kidney transplantation was observed in Korea according to wealth inequality, and this disparity was worsening.


Sujet(s)
Accessibilité des services de santé/économie , Disparités d'accès aux soins/économie , Couverture d'assurance/économie , Assurance maladie/économie , Défaillance rénale chronique/économie , Défaillance rénale chronique/chirurgie , Transplantation rénale/économie , Évaluation des résultats et des processus en soins de santé/économie , Adolescent , Adulte , Sujet âgé , Enfant , Bases de données factuelles , Femelle , Survie du greffon , Humains , Revenu , Défaillance rénale chronique/mortalité , Transplantation rénale/effets indésirables , Transplantation rénale/mortalité , Mâle , Adulte d'âge moyen , Prévalence , République de Corée/épidémiologie , Déterminants sociaux de la santé/économie , Facteurs temps , Résultat thérapeutique , Jeune adulte
17.
Ann Vasc Surg ; 70: 306-313, 2021 Jan.
Article de Anglais | MEDLINE | ID: mdl-32889161

RÉSUMÉ

BACKGROUND: The situation of coronavirus disease 2019 (COVID-19) pandemic in the Indian subcontinent is worsening. In Bangladesh, rate of new infection has been on the rise despite limited testing facility. Constraint of resources in the health care sector makes the fight against COVID-19 more challenging for a developing country like Bangladesh. Vascular surgeons find themselves in a precarious situation while delivering professional services during this crisis. With the limited number of dedicated vascular surgeons in Bangladesh, it is important to safeguard these professionals without compromising emergency vascular care services in the long term. To this end, we at the National Institute of Cardiovascular Diseases and Hospital, Dhaka, have developed a working guideline for our vascular surgeons to follow during the COVID-19 pandemic. The guideline takes into account high vascular work volume against limited resources in the country. METHODS: A total of 307 emergency vascular patients were dealt with in the first 4 COVID-19 months (March through June 2020) according to the working guideline, and the results were compared with the 4 pre-COVID-19 months. Vascular trauma, dialysis access complications, and chronic limb-threatening ischemia formed the main bulk of the patient population. Vascular health care workers were regularly screened for COVID-19 infection. RESULTS: There was a 38% decrease in the number of patients in the COVID-19 period. Treatment outcome in COVID-19 months were comparable with that in the pre-COVID-19 months except that limb loss in the chronic limb-threatening ischemia patients was higher. COVID-19 infection among the vascular health care professionals was low. CONCLUSIONS: Vascular surgery practice guidelines customized for the high work volume and limited resources of the National Institute of Cardiovascular Diseases and Hospital, Dhaka were effective in delivering emergency care during COVID-19 pandemic, ensuring safety of the caregivers. Despite the fact that similar guidelines exist in different parts of the world, we believe that the present one is still relevant on the premises of a deepening COVID-19 crisis in a developing country like Bangladesh.


Sujet(s)
COVID-19 , Pays en voie de développement , Hôpitaux à haut volume d'activité/normes , Évaluation des résultats et des processus en soins de santé/normes , Types de pratiques des médecins/normes , Chirurgiens/normes , Procédures de chirurgie vasculaire/normes , Charge de travail/normes , Bangladesh , Pays en voie de développement/économie , Coûts des soins de santé/normes , Humains , Évaluation des résultats et des processus en soins de santé/économie , Types de pratiques des médecins/économie , Chirurgiens/économie , Facteurs temps , Résultat thérapeutique , Procédures de chirurgie vasculaire/économie , Charge de travail/économie
18.
Ann Vasc Surg ; 72: 589-600, 2021 Apr.
Article de Anglais | MEDLINE | ID: mdl-33227475

RÉSUMÉ

BACKGROUND: "Structural factors" relating to organization of hospitals may affect procedural outcomes. This study's aim was to clarify associations between structural factors and outcomes after carotid endarterectomy (CEA) and carotid endarterectomy stenting (CAS). METHODS: A systematic review of studies published in English since 2005 was conducted. Structural factors assessed were as follows: population size served by the vascular department; number of hospital beds; availability of dedicated vascular beds; established clinical pathways; surgical intensive care unit (SICU) size; and specialty of surgeon/interventionalist. Primary outcomes were as follows: mortality; stroke; cardiac complications; length of hospital stay (LOS); and cost. RESULTS: There were 11 studies (n = 95,100 patients) included in this systematic review. For CEA, reduced mortality (P < 0.0001) and stroke rates (P = 0.001) were associated with vascular departments serving >75,000 people. Larger hospitals were associated with lower mortality, stroke rate, and cardiac events, compared with smaller hospitals (less than 130 beds). Provision of vascular beds after CEA was associated with lower mortality (P = 0.0008) and fewer cardiac events (P = 0.03). Adherence to established clinical pathways was associated with reduced stroke and cardiac event rates while reducing CEA costs. Large SICUs (≥7 beds) and dedicated intensivists were associated with decreased mortality after CEA while a large SICU was associated with reduced stroke rate (P = 0.001). Vascular surgeons performing CEA were associated with lower stroke rates and shorter LOS (P = 0.0001) than other specialists. CAS outcomes were not influenced by specialty but costless when performed by vascular surgeons (P < 0.0001). CONCLUSIONS: Structural factors affect CEA outcomes, but data on CAS were limited. These findings may inform reconfiguration of vascular services, reducing risks and costs associated with carotid interventions.


Sujet(s)
Artériopathies carotidiennes/thérapie , Endartériectomie carotidienne , Procédures endovasculaires , Capacité hospitalière , Évaluation des résultats et des processus en soins de santé , Amélioration de la qualité , Indicateurs qualité santé , Artériopathies carotidiennes/diagnostic , Artériopathies carotidiennes/économie , Artériopathies carotidiennes/mortalité , Analyse coût-bénéfice , Soins de réanimation , Endartériectomie carotidienne/effets indésirables , Endartériectomie carotidienne/économie , Endartériectomie carotidienne/mortalité , Procédures endovasculaires/effets indésirables , Procédures endovasculaires/économie , Procédures endovasculaires/instrumentation , Procédures endovasculaires/mortalité , Cardiopathies/étiologie , Cardiopathies/mortalité , Capacité hospitalière/économie , Coûts hospitaliers , Mortalité hospitalière , Humains , Durée du séjour , Évaluation des résultats et des processus en soins de santé/économie , Amélioration de la qualité/économie , Indicateurs qualité santé/économie , Appréciation des risques , Facteurs de risque , Endoprothèses , Accident vasculaire cérébral/étiologie , Accident vasculaire cérébral/mortalité , Facteurs temps , Résultat thérapeutique
19.
J Vasc Interv Radiol ; 32(2): 262-269, 2021 02.
Article de Anglais | MEDLINE | ID: mdl-33139185

RÉSUMÉ

PURPOSE: To evaluate time-driven activity-based costing (TDABC) in interventional radiology for image-guided vascular malformation treatment as an example. MATERIALS AND METHODS: Retrospective analysis was performed on consecutive vascular malformation treatment cycles [67 venous malformations (VMs) and 11 arteriovenous malformations (AVMs)] in a university hospital in 2018. All activities were integrated with a process map, and spent resources were assigned accordingly. TDABC uses 2 parameters: (i) practical capacity cost rate, calculated as 80% of theoretical capacity, and (ii) time consumption of each resource determined by interviews (23 items). Thereby, the total costs were calculated. Treatment cycles were modified according to identified resource waste and TDABC-guided negotiations with health insurance. RESULTS: Total personnel time required was higher for AVM (1,191 min) than for VM (637 min) treatment. The interventional procedure comprised the major part (46%) of personnel time required in AVM, whereas it comprised 19% in VM treatment. Materials represented the major cost type in AVM (75%) and VM (45%) treatments. TDABC-based treatment process modification led to a decrease in personnel time need of 16% and 30% and a cost reduction of 5.5% and 15.7% for AVM and VM treatments, respectively. TDABC-guided cost reduction and TDABC-informed negotiations improved profit from -56% to +40% and from +41% to +69% for AVM and VM treatments, respectively. CONCLUSIONS: TDABC facilitated the precise costing of interventional radiologic treatment cycles and optimized internal processes, cost reduction, and revenues. Hence, TDABC is a promising tool to determine the denominator of interventional radiology's value.


Sujet(s)
Prestations des soins de santé/économie , Coûts hospitaliers , Hôpitaux universitaires/économie , Évaluation des résultats et des processus en soins de santé/économie , Radiographie interventionnelle/économie , Anomalies vasculaires/économie , Anomalies vasculaires/thérapie , Économies , Analyse coût-bénéfice , Humains , Amélioration de la qualité/économie , Indicateurs qualité santé/économie , Études rétrospectives , Facteurs temps , Anomalies vasculaires/imagerie diagnostique , Flux de travaux , Charge de travail/économie
20.
J Vasc Surg ; 73(2): 662-673.e3, 2021 02.
Article de Anglais | MEDLINE | ID: mdl-32652115

RÉSUMÉ

BACKGROUND: The U.S. healthcare system is undergoing a broad transformation from the traditional fee-for-service model to value-based payments. The changes introduced by the Medicare Quality Payment Program, including the establishment of Alternative Payment Models, ensure that the practice of vascular surgery is likely to face significant reimbursement changes as payments transition to favor these models. The Society for Vascular Surgery Alternative Payment Model taskforce was formed to explore the opportunities to develop a physician-focused payment model that will allow vascular surgeons to continue to deliver the complex care required for peripheral arterial disease (PAD). METHODS: A financial analysis was performed based on Medicare beneficiaries who had undergone qualifying index procedures during fiscal year 2016 through the third quarter of 2017. Index procedures were defined using a list of Healthcare Common Procedural Coding (HCPC) procedure codes that represent open and endovascular PAD interventions. Inpatient procedures were mapped to three diagnosis-related group (DRG) families consistent with PAD conditions: other vascular procedures (codes, 252-254), aortic and heart assist procedures (codes, 268, 269), and other major vascular procedures (codes, 270-272). Patients undergoing outpatient or office-based procedures were included if the claims data were inclusive of the HCPC procedure codes. Emergent procedures, patients with end-stage renal disease, and patients undergoing interventions within the 30 days preceding the index procedure were excluded. The analysis included usage of postacute care services (PACS) and 90-day postdischarge events (PDEs). PACS are defined as rehabilitation, skilled nursing facility, and home health services. PDEs included emergency department visits, observation stays, inpatient readmissions, and reinterventions. RESULTS: A total of 123,180 cases were included. Of these 123,180 cases, 82% had been performed in the outpatient setting. The Medicare expenditures for all periprocedural services provided at the index procedure (ie, professional, technical, and facility fees) were higher in the inpatient setting, with an average reimbursement per index case of $18,755, $34,600, and $25,245 for DRG codes 252 to 254, DRG codes 268 and 269, and DRG codes 270 to 272, respectively. Outpatient facility interventions had an average reimbursement of $11,458, and office-based index procedures had costs of $11,533. PACS were more commonly used after inpatient index procedures. In the inpatient setting, PACS usage and reimbursement were 58.6% ($5338), 57.2% ($4192), and 55.9% ($5275) for DRG codes 252 to 254, DRG codes 268 and 269, and DRG codes 270 to 272, respectively. Outpatient facility cases required PACS for 13.7% of cases (average cost, $1352), and office-based procedures required PACS in 15% of cases (average cost, $1467). The 90-day PDEs were frequent across all sites of service (range, 38.9%-50.2%) and carried significant costs. Readmission was associated with the highest average PDE expenditure (range, $13,950-$18.934). The average readmission Medicare reimbursement exceeded that of the index procedures performed in the outpatient setting. CONCLUSIONS: The cost of PAD interventions extends beyond the index procedure and includes relevant spending during the long postoperative period. Despite the analysis challenges related to the breadth of vascular procedures and the site of service variability, the data identified potential cost-saving opportunities in the management of costly PDEs. Because of the vulnerability of the PAD patient population, alternative payment modeling using a bundled value-based approach will require reallocation of resources to provide longitudinal patient care extending beyond the initial intervention.


Sujet(s)
Coûts des soins de santé , Remboursement par l'assurance maladie/économie , Membre inférieur/vascularisation , Évaluation des résultats et des processus en soins de santé/économie , Maladie artérielle périphérique/économie , Maladie artérielle périphérique/chirurgie , Soins postopératoires/économie , Procédures de chirurgie vasculaire/économie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Régimes de rémunération à l'acte/économie , Femelle , Humains , Mâle , Adulte d'âge moyen , Modèles économiques , Bouquets de soins des patients/économie , Maladie artérielle périphérique/imagerie diagnostique , Études rétrospectives , Facteurs temps , Résultat thérapeutique , Assurance basée sur la valeur/économie , Procédures de chirurgie vasculaire/effets indésirables , Jeune adulte
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...